Solaris Pharma Corporation’s Post

Redgine’s Business Unit Head shared the origin of the Redgine Ecosystem. "The journey found us limited access to exceptional materials, leading to product quality inconsistency." The experience allowed her and the team to find the idea to make the whole integrated process from end to end, as the main problem is the plant quality. This, later, becomes a unique differentiation among other pharmaceutical industries that only focus on the downstream. And now, the Redgine Ecosystem is constructed in seven phases and involves thousands of stakeholders. Each phase represents traceable and recorded consistency in giving the best red ginger for all businesses. Each stakeholder shares the same value to build a stronger community.

Early planning sets up long-term success. Meet Paul Sohal and Nigel Cawthon during #JPM24 to discuss how Corval can jumpstart your biopharma commercialization planning.

Taking an Intro to Biotech Course at IVC to learn more about the fundamentals for the industry I work in. Incredible to see the stats on the success rate of the compounds evaluated throughout the FDA clinical Phases. (Source: "Intro to Biotech," Thieman & Palladino)

Patent cliffs are like daunting hamster-wheels that must be constantly overcome and they go round to no end. All big Pharma will inevitably face a Loss of Exclusivity on patented products and BMS is no exception to that. Despite Eliquis extending patents till 2028, BMS continues their growth by expanding and diversifying their product portfolio for a bulletproof decade in the 2030s. The company now has 12 registrational programs that will be visible over the next 18 months. Plus, the company boasts an “exciting” set of early assets that will form its next wave of medicines, the incoming CEO adds. Now we're talking firepower💥 #lossofexclusivity #patentedrugs #patentcliff #bristolmyerssquibb #bms #pharmainnovation #pharmaceuticals #drugs #fda

Thoughts on this? >> Q&A: Ken Song details RayzeBio’s path from Series A to IPO in 3 years, taking a down round and being disciplined >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #productmarketing #pharma

Who's coming to #jpm next week? Let's connect and discuss how technology can take your commercialization planning to the next level. #biotech #healthtch #jpm2024 #jpmorgan #commercialization #biopharma

Thoughts on this? >> Aardvark raises $85M to target hunger, not appetite, as it contemplates IPO, pharma deals >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #productmarketing #pharma #pharmaceutical

🎄🔬 Happy Holidays to our esteemed biopharma professionals! As we gather with loved ones and enjoy the festive cheer, it’s important to also embrace a well-deserved break. But, if you find a quiet moment amidst the holiday festivities and your curiosity for Process Analytical Technology (PAT) stirs, we’ve got just the thing for you. 📊 Explore our insightful white paper on downstream PAT in biopharma manufacturing: Hamilton Company’s Downstream CPP White Paper. It’s a perfect read for those peaceful moments during the holidays, offering valuable insights into optimizing your processes and staying ahead in the rapidly evolving world of biopharma. Download It here 👇👇👇✌️👍🏻👍🏻👍🏻👍🏻 https://lnkd.in/e3RnFde9 🧪 Whether you’re unwinding by the fire or taking a break from the holiday bustle, let’s keep the spirit of innovation alive. Wishing you a Merry Christmas and a New Year filled with breakthroughs and advancements in biopharma! #Biopharma #PAT #ProcessAnalytics #ChristmasReading #Innovation

Three takeaways and three burning questions for Chris Viehbacher's cost-cutting future at Biogen >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #healthcare #productmarketing #pharma

Some interesting insights from the Q&A with Ken Song regarding RayzeBio's journey: 1. Quick Rise to Acquisition: RayzeBio swiftly progressed from Series A to acquisition within a remarkably short timeframe, showcasing effective strategic decision-making and capital deployment. 🚀 2. Navigating Funding Challenges: Despite facing a challenging fundraising environment, RayzeBio demonstrated resilience and strategic foresight by prioritizing proper capitalization over short-term concerns about dilution. 💡 Maintaining Discipline: Throughout the IPO process, RayzeBio remained disciplined, resisting the temptation to maximize gains and ensuring a successful debut on the stock market. 📉 3. Post-IPO Interest and Acquisition: Interestingly, RayzeBio garnered substantial acquisition interest only after going public, indicating that the IPO served as a catalyst for attracting strategic partners. 🔄 4. Future of Radiopharmaceuticals: Song envisions radiopharmaceuticals evolving into a major modality, with increased commitment from pharmaceutical companies and advancements in isotope availability driving further innovation. 🧪 RayzeBio's journey offers valuable insights into biotech entrepreneurship, strategic decision-making, and the evolving landscape of pharmaceutical innovation. 🌱